RxDoctor Payments Data

David Lustig, MD

Internal Medicine · Cincinnati, OHNPI 1295776557

Payments from drug & device makers

$370in general payments, 2019–2025

Across 19 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$88
  • GSK$78
  • Pfizer$53
  • AbbVie$43
  • Boehringer Ingelheim$40
  • AstraZeneca$31
  • plus $36 from 2 others

What the payments were for

  • Food & beverage$33591%
  • Education$359%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$370 in reported general payments places this provider in the 60th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$77,172
Medicare patients
226
Services billed
6,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin107$123,750
EliquisApixaban116$106,976
TrulicityDulaglutide78$106,436
OzempicSemaglutide55$64,203
XareltoRivaroxaban79$62,099
MounjaroTirzepatide53$58,645
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$44,027
JanuviaSitagliptin Phosphate18$26,568
LinzessLinaclotide24$22,310
OxycontinOxycodone Hcl21$17,916
TradjentaLinagliptin20$11,299
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog27$8,120
Atorvastatin Calcium776$7,495
Breo ElliptaFluticasone/Vilanterol15$6,779
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$6,326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$88$165,081131 claims
Boehringer IngelheimJardiance, Tradjenta$40$135,049127 claims
PfizerEliquis$53$106,976116 claims
Novo NordiskOzempic$19$64,20355 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$78$53,16895 claims
AbbVieLinzess$43$22,31024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →